Skip to main content

Advertisement

Log in

Panitumumab Rechallenge in Chemorefractory Patients with Metastatic Colorectal Cancer

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.

    Article  PubMed  CAS  Google Scholar 

  3. Saltz LB, Clarke S, Diaz Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.

    Article  PubMed  CAS  Google Scholar 

  4. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663–71.

    Article  PubMed  CAS  Google Scholar 

  5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as firstline treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.

    Article  PubMed  CAS  Google Scholar 

  6. Santini D, Vincenzi B, Addeo R, et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol. 2012;23:2313–8.

    Article  PubMed  CAS  Google Scholar 

  7. Saif MW, Kaley K, Chu E, et al. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions. Clin Colorectal Cancer. 2010;9:315–8.

    Article  PubMed  CAS  Google Scholar 

  8. Power DG, Shah MA, Asmis TR, et al. Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience. Investig New Drugs. 2010;28:353–60.

    Article  CAS  Google Scholar 

  9. Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer. 2007;6:529–31.

    Article  PubMed  Google Scholar 

  10. Langerak A, River G, Mitchell E, et al. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports. Clin Colorectal Cancer. 2009;8:49–54.

    Article  PubMed  CAS  Google Scholar 

  11. Tomizawa Y, Fujita Y, Tamura A, et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer. 2010;68:269–72.

    Article  PubMed  Google Scholar 

  12. Hata A, Katakami N, Yoshioka H, et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011;74:268–73.

    Article  PubMed  Google Scholar 

  13. Townsend AR, Bishnoi S, Broadbridge V, et al. Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. Am J Clin Oncol. 2012; in press

  14. Santini D, Vincenzi B, La Cesa A, et al. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil and irinotecan-resistant advanced colorectal cancer patients. Oncology. 2005;69:27–34.

    Article  PubMed  CAS  Google Scholar 

  15. Grothey A, Cutsem EV, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multi center, randomized, placebo-controlled, phase 3 trial. Lancet. 2012; in press

Download references

Conflict of interest

The authors declare no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akito Hata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hata, A., Katakami, N., Fujita, S. et al. Panitumumab Rechallenge in Chemorefractory Patients with Metastatic Colorectal Cancer. J Gastrointest Canc 44, 456–459 (2013). https://doi.org/10.1007/s12029-012-9453-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-012-9453-7

Keywords

Navigation